Review article : Bacterial vaginosis in women
DOI:
https://doi.org/10.61841/kxp9mf74Keywords:
Bacterial vaginosis, Lactobacilli, women, Gardnerella vaginalisAbstract
Bacterial vaginosis is caused by the overgrowth of some bacteria naturally present in the vagina, Vaginal infection is most common in women, especially in pregnant women. The cause of this disorder is not known, nor is it caused by poor hygiene. women with vaginal bacteria Might not appear any signs or symptoms. Frequent washing and the use of scented soaps cause vaginal imbalance. The most common clinical symptoms of bacterial vaginosis include a thin homogeneous vaginal discharge, pH 4.5, the appearance of clue cells, and an amine odor after 10 percent of Potassium hydroxide. None of them no Lactobacilli in the vaginal fluid are normally detected by microscopy, Several ways of diagnosing BV, Clinical Quality Requirements, Gram Stain, Vaginal Cultures, Papanicolaou smears, Oligonucleotide probes, Gas-Liquid Chromatography, Proline Aminopeptidase Assay, Molecular Methods. This review focuses on the epidemiology, etiology, diagnosis, complications, and treatment of BV, with emphasis on the role of antimicrobial treatment options.
Downloads
References
1. Abad, C., & Safdar, N. (2009). The role of lactobacillus probiotics in the treatment or prevention of urogenital infections–a systematic review. Journal of Chemotherapy, 21(3), 243-252.
2. Ahmed, R. A., Elhag, W. I., & Abdelhalim, K. A. (2014). Characterization and identification of microorganisms associated with vaginal infections in pregnant women attending the Ribat University Hospital, Sudan. American Journal of Research Communication, 2(10), 301-309.
3. Alfonsi, G. A., Shlay, J. C., & Parker, S. (2004 .(What is the best approach for managing recurrent bacterial vaginosis? Clinical Inquiries, 2004 MU.( Amsel, F.-W. (1983). Flexible coupling: Google Patents ).
4. Anukam, K. C., Osazuwa, E., Osemene, G. I., Ehigiagbe, F., Bruce, A. W., & Reid, G. (2006). Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes and Infection, 8(12-13), 2772-2776.
5. Berza, N., Zodzika, J., Kroica, J., Reinis, A., Skadins, I., Piekuse, L . . . ,.Lukojanova, I. (2013). Association between Lactobacillus species and bacterial vaginosis-related bacteria, and bacterial vaginosis scores in small population of pregnant Latvian women. International Journal of Collaborative Research on Internal Medicine & Public Health, 5(5), 0-0.
6. Bradshaw, C. S., Morton, A. N., Hocking, J., Garland, S. M., Morris, M. B., Moss, L. M., . . . Fairley, C. K. (2006). High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. The Journal of infectious diseases, 193(11), 1478-1486.
7. Cook, R. L., Redondo-Lopez, V., Schmitt, C., Meriwether, C., & Sobel, J. D. (1992). Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. Journal of clinical microbiology, 30(4), 870-877.
8. Coughlin, G., & Secor, M. (2010). Bacterial vaginosis: update on evidence-based care.
Advance for nurse practitioners, 18(1), 41-44, 53.
9. Deese, J., Pradhan, S., Goetz, H., & Morrison, C. (201 .(8Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives. Open access journal of contraception, 9, 91.
10. Devillard, E., Burton, J. P., & Reid, G. (2005). Complexity of vaginal microflora as analyzed by PCR denaturing gradient gel electrophoresis in a patient with recurrent bacterial vaginosis. Infectious diseases in obstetrics and gynecology, 13(1), 25-30.
11. Donders, G. (2010). Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstetrical & gynecological survey, 65(7), 462-473.
12. Eastment, M. C., & McClelland, R. S. (2018). Vaginal microbiota and susceptibility to HIV.
AIDS (London, England), 32(6), 687.
13. Eschenbach, D. A., Thwin, S. S., Patton, D. L., Hooton, T. M., Stapleton, A. E., Agnew, K., .
. . Stamm, W. E. (2000). Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clinical Infectious Diseases, 30(6), 901-907.
14. Faro, S., & Skokos, C. K. (2005). The Efficacy and Safety of a Single Dose of Clindesse™ Vaginal Cream Versus a Seven-Dose Regimen of Cleocin® Vaginal Cream in Patients With Bacterial Vaginosis. Infectious diseases in obstetrics and gynecology, 13(3), 155-160.
15. Geva, A., Bornstein, J., Dan, M., Shoham, H. K., & Sobel, J. D. (2006). The VI-SENSE–vaginal discharge self-test to facilitate management of vaginal symptoms. American journal of obstetrics and gynecology, 195(5), 1351-1356.
16. Greaves, W. L., Chungafung, J., Morris, B., Haile, A., & Townsend, J. L. (1988). Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstetrics and gynecology, 72(5), 799-802.
17. Greenbaum, S., Greenbaum, G., Moran-Gilad, J., & Weintraub, A. Y. (2019). Ecological dynamics of the vaginal microbiome in relation to health and disease. American journal of obstetrics and gynecology, 220(4), 324-335.
18. Hallen, A., Påhlson, C., & Forsum, U. (1987). Bacterial vaginosis in women attending STD clinic: diagnostic criteria and prevalence of Mobiluncus spp. Sexually Transmitted Infections, 63(6), 386-389.
19. Henn, E., Kruger, T., & Siebert, T. (2005). Vaginal discharge reviewed: the adult pre-menopausal female. South African Family Practice, 47(2), 30-38.
20. Hillier, S., Krohn, M. A., Watts, D., Wolner-Hanssen, P & ,.Eschenbach, D. (1990). Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstetrics and gynecology, 76(3 Pt 1), 407-413.
21. Hillier, S. L. (1993). Diagnostic microbiology of bacterial vaginosis. American journal of obstetrics and gynecology, 169(2), 455-459.
22. Jain, J. P., Bristow, C. C., Pines, H. A., Harvey-Vera, A., Rangel, G., Staines, H., . . . Strathdee, S. A. (2018). Factors in the HIV risk environment associated with bacterial vaginosis among HIV-negative female sex workers who inject drugs in the Mexico-United States border region. BMC Public Health, 18(1), 1032.
23. Javed, A., Parvaiz, F., & Manzoor, S. (2019). Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it's associated resistance patterns. Microbial pathogenesis, 127, 21-30.
24. Johnson, S., Petzold, C., & Galask, R. (1985). Qualitative and quantitative changes of the vaginal microbial flora during the menstrual cycle. American journal of reproductive immunology and microbiology, 9(1), 1-5.
25. Larsson, P.-G., Bergström, M., Forsum, U., Jacobsson, B., Strand, A., & WÖLNER-HANSSEN, P. (2005). Bacterial vaginosis Transmission, role in genital tract infection and pregnancy outcome: an enigma: Review article III. Apmis, 113(4), 233-245.
26. Larsson, P.-G., & Forsum, U. (2005). Bacterial vaginosis–a disturbed bacterial flora and treatment enigma: Review article IV. Apmis, 113(5), 305-316.
27. Larsson, P. (1992). Treatment of bacterial vaginosis: SAGE Publications Sage UK: London, England.
28. Laxmi, U., Agrawal, S., Raghunandan, C., Randhawa, V., & Saili, A. (2012). Association of bacterial vaginosis with adverse fetomaternal outcome in women with spontaneous preterm labor: a prospective cohort study. The Journal of Maternal-Fetal & Neonatal Medicine, 25(1), 64-67.
29. Mania-Pramanik, J., Kerkar, S., & Salvi, V. (2009). Bacterial vaginosis: a cause of infertility?
International journal of STD & AIDS, 20(11), 778-781.
30. Marcone, V., Calzolari, E., & Bertini, M. (2008). Effectiveness of vaginal administration of Lactobacillus rhamnosus following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. The new microbiologica, 31(3), 429.
31. Marcone, V., Rocca, G., Lichtner, M., & Calzolari, E. (2010 .(Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. International Journal of Gynecology & Obstetrics, 110(3), 223-226.
32. Melvin, L., Glasier, A., Elton, R., & Cameron, S. (2008). pH-balanced tampons: do they effectively control vaginal pH? BJOG: An International Journal of Obstetrics & Gynaecology, 115(5), 639-645.
33. Menard, J.-P., Fenollar, F., Henry, M., Bretelle, F., & Raoult, D. (2008). Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clinical Infectious Diseases, 47(1), 33-43.
34. Menard, J.-P., Mazouni, C., Fenollar, F., Raoult, D., Boubli, L., & Bretelle, F. (2010). Diagnostic accuracy of quantitative real-time PCR assay versus clinical and Gram stain identification of bacterial vaginosis. European journal of clinical microbiology & infectious diseases, 29(12), 1547-1552.
35. Morris, M., Nicoll, A., Simms, I., Wilson, J., & Catchpole, M. (2001). Bacterial vaginosis: a public health review. BJOG: An International Journal of Obstetrics & Gynaecology, 108(5), 439-450.
36. Oduyebo, O. O., Anorlu, R. I., & Ogunsola, F. T. (2009). The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database of Systematic Reviews(3).
37. Pheifer, T. A., Forsyth, P. S., Durfee, M. A., Pollock, H. M., & Holmes, K. K. (1978). Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole. New England Journal of Medicine, 298(26), 1429-1434.
38. PIOT, P., VAN DYCK, E., GOODFELLOW, M., & FALKOW, S. (1980). A taxonomic
study of Gardnerella vaginalis (Haemophilus vaginalis) Gardner and Dukes 1955.
Microbiology, 119(2), 373-396.
39. Press, O. W., Eary, J. F., Badger, C. C., Martin, P. J., Appelbaum, F .R., Levy, R., . . . Krohn,
K. (1989). Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. Journal of Clinical Oncology, 7(8), 1027-1038.
40. Rao, P., Devi, S., Shriyan, A., Rajaram, M., & Jagdishchandra, K. (2004). Diagnosis of bacterial vaginosis in a rural setup: Comparison of clinical algorithm, smear scoring and culture by semiquantitative technique. Indian journal of medical microbiology, 22(1), 47.
41. Reid, G., Bruce, A. W., Fraser, N., Heinemann, C., Owen, J., & Henning, B. (2001). Oral probiotics can resolve urogenital infections. FEMS Immunology & Medical Microbiology, 30(1), 49-52.
42. Russo, R., Karadja, E., & De Seta, F. (2019). Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Beneficial microbes, 10(1), 19-26.
43. Salih, E. O. M. (2018). Isolation and Molecular Characterization of Bacterial Vaginosis and Human Papilloma Virus among Saudi Females Under Reproductive Age in Al-Madinah AlMonawara Region, KSA. Mogahid Mohamed El Hassan.
44. Sobel, J., Peipert, J. F., McGregor, J. A., Livengood, C., Martin, M., Robbins, J., & Wajszczuk, C. P. (2001). Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infectious diseases in obstetrics and gynecology, 9(1), 9-15.
45. Sobel, J. D., Ferris, D., Schwebke, J., Nyirjesy, P., Wiesenfeld, H. C., Peipert, J., . . . Hillier,
S. L. (2006) .(Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. American journal of obstetrics and gynecology, 194(5), 1283-1289.
46. Suresh, A., Rajesh, A., Bhat, R. M., & Rai, Y. (2009). Cytolytic vaginosis: A review. Indian journal of sexually transmitted diseases and AIDS, 30(1), 48.
47. Swidsinski, A., Doerffel, Y., Loening-Baucke, V., Swidsinski, S., Verstraelen, H., Vaneechoutte, M., . . . Mendling, W. (2010). Gardnerella biofilm involves females and males and is transmitted sexually. Gynecologic and obstetric investigation, 70(4), 256-263.
48. Swidsinski, A., Mendling, W., Loening-Baucke, V., Swidsinski, S., Dörffel, Y., Scholze, J., .
. . Verstraelen, H. (2008). An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. American journal of obstetrics and gynecology, 198(1), 97. e91-97. e96.
49. Swidsinski, A., Verstraelen, H., Loening-Baucke, V., Swidsinski, S., Mendling, W., & Halwani,Z (2013) .(Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PloS one, 8(1).
50. Thomason, J., Gelbart, S., Wilcoski, L., Peterson, A., Jilly, B., & Hamilton, P. (1988). Proline aminopeptidase activity as a rapid diagnostic test to confirm bacterial vaginosis. Obstetrics and gynecology, 71(4), 607-611.
51. Verstraelen, H., Delanghe, J., Roelens, K., Blot, S., Claeys, G., & Temmerman, M. (2005). Subclinical iron deficiency is a strong predictor of bacterial vaginosis in early pregnancy. BMC infectious diseases, 5(1), 55.
52. Verstraelen, H., & Verhelst, R. (2009). Bacterial vaginosis: an update on diagnosis and treatment. Expert review of anti-infective therapy, 7(9), 1109-1124.
53. Verstraelen, H., Verhelst, R., Vaneechoutte, M., & Temmerman, M. (2010). The epidemiology of bacterial vaginosis in relation to sexual behaviour. BMC infectious diseases, 10(1), 81.
54. Wilson, J., Lee, R., Balen, A., & Rutherford, A. (2007). Bacterial vaginal flora in relation to changing oestrogen levels. International journal of STD & AIDS, 18(5), 308-311.
55. Zhou, Y., Xu, W., Hong, K., Li, H., Zhang, J., Chen, X., . . . Wang, F. (2019). Therapeutic effects of probiotic Clostridium butyricum WZ001 on bacterial vaginosis in mice. Journal of applied microbiology, 127(2), 565-575.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
